Gordon Mills, MD, PhD

Gordon B. Mills, MD, PhD, was recruited to The University of Texas MD Anderson Cancer Center in 1994, where he holds the rank of Professor with joint appointments in Systems Biology, Breast Medical Oncology and Immunology; serves as chairman of the Department of Systems Biology; and holds highest University of Texas endowed award: the Wiess Distinguished University Chair in Cancer Medicine. Dr. Mills founded the Department of Systems Biology at the MD Anderson Cancer Center, which was the first Cancer Systems Biology Department and the second Systems Biology Department in the US. Dr. Mills is Director of the Kleberg Center for Molecular Markers; co Director of the Sheikh Zayed bin Sultan Al Nahyan Institute for Personalized Cancer Therapy and the Women’s Cancer Moonshot. The Center and the Institute are responsible for developing and implementing personalized molecular medicine at MDACC. The Women’s Cancer Moonshot is responsible for transforming outcomes for the patients with aggressive breast and ovarian cancer Dr. Mills currently serves as principal investigator or project investigator on many national peer review grants including NIH/NCI SPOREs, Stand up to Cancer, U24, U54 and PPGs, Department of Defense and Komen Foundation grants, and is a collaborator on multiple other national grants. Dr. Mills has published more than 700 papers on the molecular analysis of cancer; is listed as one of the most cited and influential scientists, has an H index over 100, holds more than 20 patents related to novel technologies and molecular markers and has co-founded an early diagnostics company. He currently sits on the scientific advisory boards of multiple companies and venture capital groups. He has recently been awarded the Komen Brinker award for Scientific Excellence, the Stand up to Cancer Laura Ziskin Prize for mentoring and the Finneran Family Prize in Translational Research.